New algorithm could spare cancer patients unnecessary CT scans for blood clots
NCT ID NCT04657120
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This study tested whether a simple checklist and blood test (the YEARS algorithm) can safely rule out pulmonary embolism (a blood clot in the lungs) in people with active cancer, compared to the standard approach of doing a CT scan on everyone. About 700 cancer patients with suspected clots were randomly assigned to either the YEARS method or a CT scan. The goal was to see if the algorithm could reduce the number of CT scans without missing dangerous clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amphia Ziekenhuis
Breda, Netherlands
-
Amsterdam UMC
Amsterdam, Netherlands
-
Antwerpen University Hospital (UZA)
Antwerp, Belgium
-
Bernhoven Ziekenhuis
Uden, Netherlands
-
CHU Brest
Brest, 29609, France
-
CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
-
CHU Saint-Etienne
Saint-Etienne, 42055, France
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
-
Centre Hospitalier Universitaire de Liège (CHU Liège)
Liège, Belgium
-
Cliniques Universitaires Saint-Luc (CUSL)
Brussels, Belgium
-
Diakonessenhuis
Utrecht, Netherlands
-
Flevoziekenhuis
Almere Stad, Netherlands
-
Fondazione Policlinico Universitario A. Gemelli IRCCS
Roma, Italy
-
Groene Hart Ziekenhuis
Gouda, Netherlands
-
HEGP
Paris, 75015, France
-
Haaglanden Medisch Centrum
The Hague, Netherlands
-
Hospital Universitario Ramón y Cajal
Madrid, Spain
-
Hôpital Louis Mourier - APHP
Colombes, 92700, France
-
Hôpitaux Universitaires de Genève (HUG)
Geneva, Switzerland
-
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
-
Leiden University Medical Center
Leiden, Netherlands
-
Maasstad Ziekenhuis
Rotterdam, Netherlands
-
Policlinico di Milano Ospedale Maggiore | Fondazione IRCCS Ca' Granda
Milan, Italy
-
Radboud UMC
Nijmegen, Netherlands
-
Reinier de Graaf Gasthuis
Delft, Netherlands
-
Rijnstate Ziekenhuis
Arnhem, Netherlands
-
Tergooi MC
Hilversum, Netherlands
-
The Inselspital Bern
Bern, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
YEARS algorithm (a clinical decision rule using symptoms and D-dimer blood test)
What this could lead to
If successful, this could provide a safer, faster way to diagnose or rule out blood clots in the lungs for cancer patients, reducing unnecessary radiation from CT scans.
What could go wrong
This is a completed study, but the algorithm may not be as accurate in all cancer types or settings. There is a small risk of missing a clot, which could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.